
THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE RESOLUTION

No. 295 Session of
2018

INTRODUCED BY SCHWANK, DINNIMAN, FONTANA, GREENLEAF, BREWSTER,
BARTOLOTTA, BROWNE, FOLMER, KILLION, BAKER, FARNESE,
RAFFERTY, MENSCH, COSTA, HUGHES, BOSCOLA, AUMENT AND
SCAVELLO, MARCH 26, 2018

INTRODUCED AND ADOPTED, MARCH 26, 2018

A RESOLUTION

1 Designating the month of March 2018 as "Fibromuscular Dysplasia
2 Awareness Month" in Pennsylvania.

3 WHEREAS, Fibromuscular dysplasia (FMD) is a disease that
4 causes abnormal cell growth of the arterial walls in the body
5 and can lead to areas of narrowing, beading, aneurysms and
6 tearing of areas of the arterial wall; and

7 WHEREAS, FMD is usually detected by accident or as a result
8 of a serious incident because its symptoms, including
9 hypertension, headaches and dizziness, affect much of the
10 general population; and

11 WHEREAS, There has been little progress in understanding the
12 disease since it was first diagnosed in 1938; and

13 WHEREAS, There is no known cause or cure for the disease, and
14 there are no set protocols for treatment; and

15 WHEREAS, FMD is classified as a rare disease, though many
16 researchers believe it is underdiagnosed; and

17 WHEREAS, Ninety percent of patients affected by FMD are

1 women, but men and children also get the disease; and

2 WHEREAS, There are different classifications of FMD, with the
3 two most common types being medial fibroplasia and intimal
4 fibroplasia, but there is no understanding of what causes the
5 differences; and

6 WHEREAS, Unlike the adult population, children tend to be
7 diagnosed with intimal fibroplasia, a more aggressive disease;
8 and

9 WHEREAS, Individuals and families affected by fibromuscular
10 dysplasia often experience problems such as a sense of
11 isolation, difficulty in obtaining accurate and timely diagnosis
12 and optimal treatment options; and

13 WHEREAS, Women between 20 and 60 years of age comprise 90% of
14 patients diagnosed with FMD; and

15 WHEREAS, Individuals and families affected by FMD often
16 experience isolation, difficulty in obtaining an accurate and
17 timely diagnosis and less than optimal treatment options, and
18 often patients must educate their own physicians about the
19 disease; and

20 WHEREAS, The Fibromuscular Dysplasia Society of America
21 (FMDSA) was founded in March 2003 and over the past 14 years has
22 been active and successful in raising public and medical
23 professional awareness of the disease, increasing patient
24 support and working with researchers around the world; and

25 WHEREAS, FMDSA is also funding the United States Registry for
26 Fibromuscular Dysplasia; and

27 WHEREAS, FMDSA is organizing a global observance of FMD to
28 have patients, medical professionals and researchers join
29 together to focus attention on FMD as a public health issue;
30 therefore be it

1 RESOLVED, That the Senate designate the month of March 2018
2 as "Fibromuscular Dysplasia Awareness Month" in Pennsylvania.